The core CDMO business is burning cash faster than revenue grows, and the $2.9M cash position provides limited runway without additional financing. The failed PC111 grant submission removes a key near-term catalyst and raises doubt about the PinCell option. Monitor for a definitive agreement on the U.S. clinical manufacturing program and any further equity dilution via the SEPA facility. The stock remains at high risk of Nasdaq delisting given the sub-$1 bid price.
Price Chart
Executive Summary
Scinai Immunotherapeutics reported H1 2026 results with revenue up to $949K (from $773K YoY) but gross loss widened to $2.4M from $1.3M as CDMO costs outpace revenue. Net income of $1.6M was entirely driven by a $6.4M non-cash bargain purchase gain from the Recipharm acquisition; operating loss deepened to $4.6M from $3.8M. Cash burn remains high at $3.9M operating cash outflow, leaving $2.9M in cash. A key U.S. CDMO program is expanding but lacks a definitive agreement, and the PC111 grant application was botched by an external consultant, delaying the PinCell option path. The stock trades near a $2M market cap with ongoing Nasdaq delisting risk.
Key Facts
- Revenue increased to $949K for H1 2026 vs $773K in H1 2025, driven by the acquired Yavne CDMO operations.
- Gross loss widened to $2.4M from $1.3M as cost of revenues ($3.3M) far exceeded revenue.
- Operating loss deepened to $4.6M from $3.8M; net income of $1.6M was entirely due to a $6.4M non-cash bargain purchase gain from the Recipharm acquisition.
- Cash, cash equivalents and restricted cash totaled $2.9M as of June 30, 2026; net cash used in operating activities was $3.9M.
- Committed Customer Orders reached ~$3.1M as of August 16, 2026, with ~$2.1M invoiced.
- A U.S. biopharma customer expanded a feasibility project into a broader clinical manufacturing/CMC program; ~$650K received in cash payments/advances but no definitive agreement yet.
- The PC111 grant application under the Polish FENG program was not submitted due to an administrative error by the external grant consultant; PinCell option extension is under discussion.
- The company completed a 1-for-10 ADS reverse split effective August 21, 2026.
- Share count ballooned to 22.8B ordinary shares at June 30, 2026 from 13.9B at year-end 2025, reflecting massive dilution from warrant exercises and SEPA draws.
Financial Impact
Operating cash burn of $3.9M in H1 2026 vs $2.6M in H1 2025; cash position of $2.9M provides limited runway. Revenue of $949K is insufficient to cover $3.3M cost of revenues. The $6.4M bargain purchase gain is non-cash and non-recurring.
Risk Factors
- Cash runway is limited with $2.9M and $3.9M H1 operating cash burn; likely need for dilutive financing soon.
- Nasdaq delisting risk persists with sub-$1 bid price despite the reverse split.
- PC111/PinCell option path is uncertain after the grant application failure; no definitive amendment yet.
- The expanded U.S. CDMO program lacks a definitive agreement; scope and timing are uncertain.
- Massive shareholder dilution continues via SEPA draws and warrant exercises.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-093738 |
| Document: 0001213900-26-093738-index.html | 0001213900-26-093738 |
| Document: 0001213900-26-093738.txt | 0001213900-26-093738 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5310 (−22.06%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5310 (+29.39%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5310 (+29.43%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5310 (+41.10%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5310 (−56.83%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5310 (+56.48%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5310 (−68.58%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5310 (+81.50%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5310 (−93.80%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5310 (+57.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers